



CareSource considers Qalsody (tofersen) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off -Label policy.

DATE	ACTION/DESCRIPTION
05/08/2023	New policy for Qalsody created.

References:

1. Qalsody [prescribing information]. Biogen MA Inc.; 2023.
2. Miller TM, Cudkowicz ME, Genge A, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099-1110. doi:10.1056/NEJMoa2204705
3. van den Berg LH, Sorenson E, Gronseth G, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610-e1623. doi:10.1212/WNL.0000000000007242
4. ALS Functional Rating Scale. Available at: <http://www.outcomes-umassmed.org/als/alsscale.aspx>.

Effective date: 10/01/2023

Revised date: 05/08/2023